Background: Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for estrogen receptor-positive breast cancer treatment, yet many of these cancers are intrinsically resistant to tamoxifen or acquire resistance during treatment. Therefore, scientists are searching for breast cancer drugs that have different molecular targets. Methodology: Recently, a computational approach was used to successfully design peptides that are new lead compounds against breast cancer. We used replica exchange molecular dynamics to predict the structure and dynamics of active peptides, leading to the discovery of smaller bioactive peptides. Conclusions: These analogs inhibit estrogen-dependent cell growth in a mouse uterine growth a...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Background: Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for...
Breast cancer is the most common cancer among women, and tamoxifen is the preferred drug for estroge...
Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for estrogen re...
Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for estrogen re...
Drug research and discovery are of critical importance in human health care. Computational approache...
Breast cancer cells are spread to new locations in the body via metastasis. Inflammatory cytokines p...
Breast cancer cells are spread to new locations in the body via metastasis. Inflammatory cytokines p...
Introduction: It has long been considered that the most significant risks for breast cancer are gend...
Introduction: It has long been considered that the most significant risks for breast cancer are gend...
Membranolytic anticancer peptides represent a potential strategy in the fight against cancer. Howeve...
Drug discovery and development are intense, lengthy and interdisciplinary processes. Traditionally, ...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Background: Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for...
Breast cancer is the most common cancer among women, and tamoxifen is the preferred drug for estroge...
Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for estrogen re...
Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for estrogen re...
Drug research and discovery are of critical importance in human health care. Computational approache...
Breast cancer cells are spread to new locations in the body via metastasis. Inflammatory cytokines p...
Breast cancer cells are spread to new locations in the body via metastasis. Inflammatory cytokines p...
Introduction: It has long been considered that the most significant risks for breast cancer are gend...
Introduction: It has long been considered that the most significant risks for breast cancer are gend...
Membranolytic anticancer peptides represent a potential strategy in the fight against cancer. Howeve...
Drug discovery and development are intense, lengthy and interdisciplinary processes. Traditionally, ...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...
Introduction: The vast majority of breast cancers (BC) are estrogen receptor positive (ER+). The mos...